Skip to main content
Top
Published in: Malaria Journal 1/2020

01-12-2020 | Plasmodium Falciparum | Review

Evaluation of residual submicroscopic Plasmodium falciparum parasites 3 days after initiation of treatment with artemisinin-based combination therapy

Authors: Richard Mwaiswelo, Bill Ngasala

Published in: Malaria Journal | Issue 1/2020

Login to get access

Abstract

Plasmodium falciparum resistance against artemisinin has not emerged in Africa; however, there are reports of the presence of polymerase chain reaction-determined residual submicroscopic parasitaemia detected on day 3 after artemisinin-based combination therapy (ACT). These residual submicroscopic parasites are thought to represent tolerant/resistant parasites against artemisinin, the fast-acting component of the combination. This review focused on residual submicroscopic parasitaemia, what it represents, and its significance on the emergence and spread of artemisinin resistance in Africa. Presence of residual submicroscopic parasitemia on day 3 after treatment initiation leaves question on whether successful treatment is attained with ACT. Thus there is a need to determine the potential public health implication of the PCR-determined residual submicroscopic parasitaemia observed on day 3 after ACT. Robust techniques, such as in vitro cultivation, should be used to evaluate if the residual submicroscopic parasites detected on day 3 after ACT are viable asexual parasites, or gametocytes, or the DNA of the dead parasites waiting to be cleared from the circulation. Such techniques would also evaluate the transmissibility of these residual parasites.
Literature
1.
go back to reference WHO. World Malaria Report 2005. Geneva: World Health Organization; 2005. WHO. World Malaria Report 2005. Geneva: World Health Organization; 2005.
2.
go back to reference WHO. World Malaria Report 2010. Geneva: World Health Organization; 2010. WHO. World Malaria Report 2010. Geneva: World Health Organization; 2010.
3.
go back to reference WHO. World Malaria Report 2017. Geneva: World Health Organization; 2017. WHO. World Malaria Report 2017. Geneva: World Health Organization; 2017.
4.
go back to reference Björkman A, Shakely D, Ali AS, Morris U, Mkali H, Abbas AK, et al. From high to low malaria transmission in Zanzibar—challenges and opportunities to achieve elimination. BMC Med. 2019;17:14.PubMedPubMedCentralCrossRef Björkman A, Shakely D, Ali AS, Morris U, Mkali H, Abbas AK, et al. From high to low malaria transmission in Zanzibar—challenges and opportunities to achieve elimination. BMC Med. 2019;17:14.PubMedPubMedCentralCrossRef
5.
go back to reference Dondorp A, Nosten F, Das D, Phyo AP, Tarning J, Lwin KM, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.PubMedPubMedCentralCrossRef Dondorp A, Nosten F, Das D, Phyo AP, Tarning J, Lwin KM, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.PubMedPubMedCentralCrossRef
6.
go back to reference Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51:e82–9.PubMedCrossRef Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51:e82–9.PubMedCrossRef
7.
go back to reference Ashley E, Dhorda M, Fairhurst R, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.PubMedPubMedCentralCrossRef Ashley E, Dhorda M, Fairhurst R, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.PubMedPubMedCentralCrossRef
8.
go back to reference Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.PubMedCrossRef Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.PubMedCrossRef
9.
go back to reference White LJ, Flegg JA, Phyo AP, Wiladpai-ngern JH, Bethell D, Plowe C, et al. Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. PLoS Med. 2015;12:e1001823.PubMedPubMedCentralCrossRef White LJ, Flegg JA, Phyo AP, Wiladpai-ngern JH, Bethell D, Plowe C, et al. Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. PLoS Med. 2015;12:e1001823.PubMedPubMedCentralCrossRef
10.
go back to reference Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272–80.PubMedCrossRef Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272–80.PubMedCrossRef
11.
go back to reference Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. Fed Eur Biochem Soc Lett. 2011;585:1551–62.CrossRef Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. Fed Eur Biochem Soc Lett. 2011;585:1551–62.CrossRef
12.
go back to reference Ajayi NA, Ukwaja KN. Possible artemisinin-based combination therapy-resistant malaria in Nigeria: a report of three cases. Rev da Soc Bras Med Trop. 2013;46:525–7.CrossRef Ajayi NA, Ukwaja KN. Possible artemisinin-based combination therapy-resistant malaria in Nigeria: a report of three cases. Rev da Soc Bras Med Trop. 2013;46:525–7.CrossRef
13.
go back to reference Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376:991–3.PubMedCrossRef Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376:991–3.PubMedCrossRef
14.
go back to reference Taylor SM, Parobek CM, Deconti DK, Kayentao K, Coulibaly SO, Meshnick SR, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015;211:680–8.PubMedCrossRef Taylor SM, Parobek CM, Deconti DK, Kayentao K, Coulibaly SO, Meshnick SR, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015;211:680–8.PubMedCrossRef
15.
go back to reference Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-saharan Africa. J Infect Dis. 2015;211:1352–5.PubMed Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-saharan Africa. J Infect Dis. 2015;211:1352–5.PubMed
16.
go back to reference WHO. World Malaria Report. Geneva: World Health Organization; 2015. WHO. World Malaria Report. Geneva: World Health Organization; 2015.
17.
go back to reference Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK, et al. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis. 2013;208:2017–24.PubMedPubMedCentralCrossRef Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK, et al. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis. 2013;208:2017–24.PubMedPubMedCentralCrossRef
18.
go back to reference Carlsson AM, Ngasala BE, Dahlström S, Membi C, Veiga IM, Rombo L, et al. Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria. Malar J. 2011;10:380.PubMedPubMedCentralCrossRef Carlsson AM, Ngasala BE, Dahlström S, Membi C, Veiga IM, Rombo L, et al. Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria. Malar J. 2011;10:380.PubMedPubMedCentralCrossRef
19.
go back to reference Chang H, Meibalan E, Zelin J, Daniels R, Eziefula AC, Meyer EC, et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Sci Rep. 2016;6:26330.PubMedPubMedCentralCrossRef Chang H, Meibalan E, Zelin J, Daniels R, Eziefula AC, Meyer EC, et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Sci Rep. 2016;6:26330.PubMedPubMedCentralCrossRef
20.
go back to reference Kiaco K, Teixeira J, Machado M, do Rosário V, Lopes D. Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and k13-propeller polymorphisms in Luanda, Angola. Malar J. 2015;14:504.PubMedPubMedCentralCrossRef Kiaco K, Teixeira J, Machado M, do Rosário V, Lopes D. Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and k13-propeller polymorphisms in Luanda, Angola. Malar J. 2015;14:504.PubMedPubMedCentralCrossRef
21.
go back to reference Mwaiswelo R, Ngasala B, Jovel I, Xu W, Larson E, Malmberg M, et al. Prevalence of and risk factors associated with polymerase chain reaction-determined Plasmodium falciparum positivity on day 3 after initiation of artemether–lumefantrine treatment for uncomplicated malaria in Bagamoyo district, Tanzania. Am J Trop Med Hyg. 2019;100:1179–86.PubMedPubMedCentralCrossRef Mwaiswelo R, Ngasala B, Jovel I, Xu W, Larson E, Malmberg M, et al. Prevalence of and risk factors associated with polymerase chain reaction-determined Plasmodium falciparum positivity on day 3 after initiation of artemether–lumefantrine treatment for uncomplicated malaria in Bagamoyo district, Tanzania. Am J Trop Med Hyg. 2019;100:1179–86.PubMedPubMedCentralCrossRef
22.
go back to reference Abdul-Ghani R, Mahdy MAK, Beier JC, Basco LK. Hidden reservoir of resistant parasites: the missing link in the elimination of falciparum malaria. Infect Dis Poverty. 2017;6:12.PubMedPubMedCentralCrossRef Abdul-Ghani R, Mahdy MAK, Beier JC, Basco LK. Hidden reservoir of resistant parasites: the missing link in the elimination of falciparum malaria. Infect Dis Poverty. 2017;6:12.PubMedPubMedCentralCrossRef
23.
go back to reference WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
24.
go back to reference Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.PubMedCentralCrossRef Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.PubMedCentralCrossRef
25.
go back to reference Roth JM, Sawa P, Omweri G, Makio N, Osoti V, De Jong MD, et al. Molecular detection of residual parasitemia after pyronaridine–artesunate or artemether–lumefantrine treatment of uncomplicated Plasmodium falciparum malaria in Kenyan Children. Am J Trop Med Hyg. 2018;99:970–7.PubMedPubMedCentralCrossRef Roth JM, Sawa P, Omweri G, Makio N, Osoti V, De Jong MD, et al. Molecular detection of residual parasitemia after pyronaridine–artesunate or artemether–lumefantrine treatment of uncomplicated Plasmodium falciparum malaria in Kenyan Children. Am J Trop Med Hyg. 2018;99:970–7.PubMedPubMedCentralCrossRef
27.
go back to reference Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White N. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697–704.PubMedPubMedCentralCrossRef Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White N. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697–704.PubMedPubMedCentralCrossRef
28.
go back to reference Ezzet F, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol. 1998;46:553–61.PubMedPubMedCentralCrossRef Ezzet F, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol. 1998;46:553–61.PubMedPubMedCentralCrossRef
31.
go back to reference Lin JT. Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep. 2011;12:165–73.CrossRef Lin JT. Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep. 2011;12:165–73.CrossRef
33.
go back to reference Sibley CH, Price RN. Monitoring antimalarial drug resistance: applying lessons learned from the past in a fast-moving present. Int J Parasitol Drugs Drug Resist. 2012;2:126–33.PubMedPubMedCentralCrossRef Sibley CH, Price RN. Monitoring antimalarial drug resistance: applying lessons learned from the past in a fast-moving present. Int J Parasitol Drugs Drug Resist. 2012;2:126–33.PubMedPubMedCentralCrossRef
35.
go back to reference WWARN. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Med. 2015;13:212.CrossRef WWARN. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Med. 2015;13:212.CrossRef
36.
go back to reference Méndez F, Muñoz Á, Carrasquilla G, Jurado D, Arévalo-herrera M, Cortese JF, et al. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol. 2002;156:230–8.PubMedCrossRef Méndez F, Muñoz Á, Carrasquilla G, Jurado D, Arévalo-herrera M, Cortese JF, et al. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol. 2002;156:230–8.PubMedCrossRef
37.
go back to reference Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirjaroen L, ter Kuile F, et al. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg. 2001;65:614–22.PubMedCrossRef Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirjaroen L, ter Kuile F, et al. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg. 2001;65:614–22.PubMedCrossRef
38.
go back to reference WHO. Artemisinin and artemisinin-based combination therapy resistance. Geneva: World Health Organization; 2016. WHO. Artemisinin and artemisinin-based combination therapy resistance. Geneva: World Health Organization; 2016.
39.
go back to reference WHO. Update on artemisinin resistance. Geneva: World Health Organization; 2012. WHO. Update on artemisinin resistance. Geneva: World Health Organization; 2012.
40.
go back to reference Yavo W, Faye B, Kuete T, Djohan V, Oga SA, Kassi RR, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar J. 2011;10:198.PubMedPubMedCentralCrossRef Yavo W, Faye B, Kuete T, Djohan V, Oga SA, Kassi RR, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar J. 2011;10:198.PubMedPubMedCentralCrossRef
41.
go back to reference Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in mainland Tanzania. Malar J. 2018;17:369.PubMedPubMedCentralCrossRef Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in mainland Tanzania. Malar J. 2018;17:369.PubMedPubMedCentralCrossRef
42.
go back to reference Adam I, Ibrahim Y, Gasim GI. Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. Malar J. 2018;17:110.PubMedPubMedCentralCrossRef Adam I, Ibrahim Y, Gasim GI. Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. Malar J. 2018;17:110.PubMedPubMedCentralCrossRef
43.
go back to reference Mideo N, Jeffrey A, Hathaway N, Ngasala B, Saunders D, Lon C, et al. A deep-sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections. Evol Med Public Health. 2016;2016:e1093.CrossRef Mideo N, Jeffrey A, Hathaway N, Ngasala B, Saunders D, Lon C, et al. A deep-sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections. Evol Med Public Health. 2016;2016:e1093.CrossRef
44.
go back to reference Bosman A, Cunningham J. WHO Evidence Review Group on malaria submicroscopic infections 2017. Geneva: World Health Organization; 2017. Bosman A, Cunningham J. WHO Evidence Review Group on malaria submicroscopic infections 2017. Geneva: World Health Organization; 2017.
45.
go back to reference Lopera-Mesa TM, Doumbia S, Chiang S, Zeituni AE, Konate DS, Doumbouya M, et al. Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis. 2013;207:1655–63.PubMedPubMedCentralCrossRef Lopera-Mesa TM, Doumbia S, Chiang S, Zeituni AE, Konate DS, Doumbouya M, et al. Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis. 2013;207:1655–63.PubMedPubMedCentralCrossRef
46.
go back to reference Maiga AW, Fofana B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87:23–8.PubMedPubMedCentralCrossRef Maiga AW, Fofana B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87:23–8.PubMedPubMedCentralCrossRef
47.
go back to reference Mwaiswelo R, Ngasala B, Jovel I, Aydin-Schmidt B, Gosling R, Premji Z, et al. Adding a single low-dose of primaquine (0.25 mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial. Malar J. 2016;15:316.PubMedPubMedCentralCrossRef Mwaiswelo R, Ngasala B, Jovel I, Aydin-Schmidt B, Gosling R, Premji Z, et al. Adding a single low-dose of primaquine (0.25 mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial. Malar J. 2016;15:316.PubMedPubMedCentralCrossRef
48.
go back to reference Henriques G, Hallett RL, Beshir KB, Gadalla NB, Johnson RE, Burrow R, et al. Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J Infect Dis. 2014;210:2001–8.PubMedPubMedCentralCrossRef Henriques G, Hallett RL, Beshir KB, Gadalla NB, Johnson RE, Burrow R, et al. Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J Infect Dis. 2014;210:2001–8.PubMedPubMedCentralCrossRef
49.
go back to reference Djimdé A, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003;69:558–63.PubMedCrossRef Djimdé A, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003;69:558–63.PubMedCrossRef
50.
go back to reference Hastings IM, Kay K, Hodel EM. How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance? Antimicrob Agents Chemother. 2015;59:6428–36.PubMedPubMedCentralCrossRef Hastings IM, Kay K, Hodel EM. How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance? Antimicrob Agents Chemother. 2015;59:6428–36.PubMedPubMedCentralCrossRef
51.
go back to reference WHO. World Malaria Report 2016. Geneva: World Health Organization; 2016. WHO. World Malaria Report 2016. Geneva: World Health Organization; 2016.
52.
go back to reference Mwaiswelo R, Ngasala B, Gil JP, Malmberg M, Jovel I, Xu W, et al. Sustained high cure rate of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria after 8 years of its wide-scale use in Bagamoyo district, Tanzania. Am J Trop Med Hyg. 2017;97:526–32.PubMedPubMedCentralCrossRef Mwaiswelo R, Ngasala B, Gil JP, Malmberg M, Jovel I, Xu W, et al. Sustained high cure rate of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria after 8 years of its wide-scale use in Bagamoyo district, Tanzania. Am J Trop Med Hyg. 2017;97:526–32.PubMedPubMedCentralCrossRef
53.
go back to reference Thriemer K, Van Hong N, Rosanas-Urgell A, Phuc BQ, Ha DM, Pockele E, et al. Delayed parasite clearance after treatment with dihydroartemisini-piperaquine in Plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Chemother. 2014;58:7049–55.PubMedPubMedCentralCrossRef Thriemer K, Van Hong N, Rosanas-Urgell A, Phuc BQ, Ha DM, Pockele E, et al. Delayed parasite clearance after treatment with dihydroartemisini-piperaquine in Plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Chemother. 2014;58:7049–55.PubMedPubMedCentralCrossRef
54.
go back to reference Tun KM, Jeeyapant A, Imwong M, Thein M, Soe S, Aung M, et al. Parasite clearance rates in upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malar J. 2016;15:185.PubMedPubMedCentralCrossRef Tun KM, Jeeyapant A, Imwong M, Thein M, Soe S, Aung M, et al. Parasite clearance rates in upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malar J. 2016;15:185.PubMedPubMedCentralCrossRef
55.
go back to reference WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
56.
go back to reference WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy. Geneva: World Health Organization; 2018. WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy. Geneva: World Health Organization; 2018.
57.
go back to reference Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, et al. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother. 2011;55:5408–11.PubMedPubMedCentralCrossRef Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, et al. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother. 2011;55:5408–11.PubMedPubMedCentralCrossRef
58.
go back to reference WHO. Global report on antimalarial drug efficacy and drug resistance: 2000-2010. Geneva: World Health Organization; 2010. WHO. Global report on antimalarial drug efficacy and drug resistance: 2000-2010. Geneva: World Health Organization; 2010.
59.
go back to reference Ferreira PE, Holmgren G, Veiga MI, Uhlen P, Kaneko A, Gil JP. PfMDR1: mechanisms of transport modulation by functional polymorphisms. PLoS ONE. 2011;6:e23875.PubMedPubMedCentralCrossRef Ferreira PE, Holmgren G, Veiga MI, Uhlen P, Kaneko A, Gil JP. PfMDR1: mechanisms of transport modulation by functional polymorphisms. PLoS ONE. 2011;6:e23875.PubMedPubMedCentralCrossRef
60.
go back to reference Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, et al. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar J. 2013;12:103.PubMedPubMedCentralCrossRef Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, et al. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar J. 2013;12:103.PubMedPubMedCentralCrossRef
61.
go back to reference Sisowath C, Petersen I, Veiga MI, Mårtensson A, Premji Z, Björkman A, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009;199:750–7.PubMedCrossRef Sisowath C, Petersen I, Veiga MI, Mårtensson A, Premji Z, Björkman A, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009;199:750–7.PubMedCrossRef
62.
go back to reference Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833–43.PubMedPubMedCentralCrossRef Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833–43.PubMedPubMedCentralCrossRef
63.
go back to reference Baliraine FN, Rosenthal PJ. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis. 2011;204:1120–4.PubMedPubMedCentralCrossRef Baliraine FN, Rosenthal PJ. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis. 2011;204:1120–4.PubMedPubMedCentralCrossRef
64.
go back to reference Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-ratto C, Mbonye MK. Variants by artemether-lumefantrine and dihydroartemisinin- piperaquine in Burkina Faso. Antimicrob Agents Chemother. 2015;59:734–7.PubMedCrossRef Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-ratto C, Mbonye MK. Variants by artemether-lumefantrine and dihydroartemisinin- piperaquine in Burkina Faso. Antimicrob Agents Chemother. 2015;59:734–7.PubMedCrossRef
65.
go back to reference Okombo J, Kamau AW, Marsh K, Sutherland CJ, Ochola-oyier LI. Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya. Int J Parasitol Drugs Drug Resist. 2014;4:152–63.PubMedPubMedCentralCrossRef Okombo J, Kamau AW, Marsh K, Sutherland CJ, Ochola-oyier LI. Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya. Int J Parasitol Drugs Drug Resist. 2014;4:152–63.PubMedPubMedCentralCrossRef
66.
go back to reference Muwanguzi J, Henriques G, Sawa P, Bousema T, Sutherland CJ, Beshir KB. Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children. Malar J. 2016;15:36.PubMedPubMedCentralCrossRef Muwanguzi J, Henriques G, Sawa P, Bousema T, Sutherland CJ, Beshir KB. Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children. Malar J. 2016;15:36.PubMedPubMedCentralCrossRef
67.
go back to reference Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, et al. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis. 2013;207:842–7.PubMedCrossRef Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, et al. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis. 2013;207:842–7.PubMedCrossRef
68.
go back to reference Asenath A, Chebon LJ, Mitei K, Opot B, Juma DW, Nyerere A, et al. Investigation of markers of artemisinin resistance at selected intervals during the 72 h period after artemisinin based combination therapy dosing in Kisumu, western Kenya. Adv Tech Biol Med. 2018;6:2.CrossRef Asenath A, Chebon LJ, Mitei K, Opot B, Juma DW, Nyerere A, et al. Investigation of markers of artemisinin resistance at selected intervals during the 72 h period after artemisinin based combination therapy dosing in Kisumu, western Kenya. Adv Tech Biol Med. 2018;6:2.CrossRef
69.
go back to reference Baraka V, Mavoko HM, Nabasumba C, Francis F, Lutumba P, Alifrangis M, et al. Impact of treatment and re-treatment with amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda. PLoS ONE. 2018;13:e0191922.PubMedPubMedCentralCrossRef Baraka V, Mavoko HM, Nabasumba C, Francis F, Lutumba P, Alifrangis M, et al. Impact of treatment and re-treatment with amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda. PLoS ONE. 2018;13:e0191922.PubMedPubMedCentralCrossRef
70.
go back to reference Lo E, Nguyen J, Oo W, Hemming-schroeder E, Zhou G, Yang Z. Examining Plasmodium falciparum and P vivax clearance subsequent to antimalarial drug treatment in the Myanmar-China border area based on quantitative real-time polymerase chain reaction. BMC Infect Dis. 2016;16:154.PubMedPubMedCentralCrossRef Lo E, Nguyen J, Oo W, Hemming-schroeder E, Zhou G, Yang Z. Examining Plasmodium falciparum and P vivax clearance subsequent to antimalarial drug treatment in the Myanmar-China border area based on quantitative real-time polymerase chain reaction. BMC Infect Dis. 2016;16:154.PubMedPubMedCentralCrossRef
71.
go back to reference Tadesse FG, Lanke K, Nebie I, Schildkraut JA, Gonçalves BP, Tiono AB, et al. Molecular markers for sensitive detection of Plasmodium falciparum asexual stage parasites and their application in a malaria clinical trial. Am J Trop Med Hyg. 2017;97:188–98.PubMedPubMedCentralCrossRef Tadesse FG, Lanke K, Nebie I, Schildkraut JA, Gonçalves BP, Tiono AB, et al. Molecular markers for sensitive detection of Plasmodium falciparum asexual stage parasites and their application in a malaria clinical trial. Am J Trop Med Hyg. 2017;97:188–98.PubMedPubMedCentralCrossRef
72.
go back to reference Pöschl B, Waneesorn J, Thekisoe O, Chutipongvivate S, Panagiotis K. Comparative diagnosis of malaria infections by microscopy, nested PCR, and LAMP in Northern Thailand. Am J Trop Med Hyg. 2010;83:56–60.PubMedPubMedCentralCrossRef Pöschl B, Waneesorn J, Thekisoe O, Chutipongvivate S, Panagiotis K. Comparative diagnosis of malaria infections by microscopy, nested PCR, and LAMP in Northern Thailand. Am J Trop Med Hyg. 2010;83:56–60.PubMedPubMedCentralCrossRef
73.
go back to reference Jarra W, Snounou G. Only viable parasites are detected by PCR following clearance of rodent malarial infections by drug treatment or immune responses. Infect Immun. 1998;66:3783–7.PubMedPubMedCentralCrossRef Jarra W, Snounou G. Only viable parasites are detected by PCR following clearance of rodent malarial infections by drug treatment or immune responses. Infect Immun. 1998;66:3783–7.PubMedPubMedCentralCrossRef
74.
go back to reference Schneider P, Wolters L, Schoone G, Schallig H, Sillekens P, Hermsen R, et al. Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparum. J Clin Microbiol. 2005;43:402–5.PubMedPubMedCentralCrossRef Schneider P, Wolters L, Schoone G, Schallig H, Sillekens P, Hermsen R, et al. Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparum. J Clin Microbiol. 2005;43:402–5.PubMedPubMedCentralCrossRef
75.
go back to reference Snounou G, Viriyakosol S, Xin PZ, Jarra W, Pinheiro L, Rosario VE, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61:315–20.PubMedCrossRef Snounou G, Viriyakosol S, Xin PZ, Jarra W, Pinheiro L, Rosario VE, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61:315–20.PubMedCrossRef
76.
go back to reference Xu W, Morris U, Aydin-schmidt B, Msellem MI, Shakely D, Petzold M, et al. SYBR green real-time PCR-RFLP assay targeting the Plasmodium cytochrome b gene—a highly sensitive molecular tool for malaria parasite detection and species determination. PLoS ONE. 2015;10:e0120210.PubMedPubMedCentralCrossRef Xu W, Morris U, Aydin-schmidt B, Msellem MI, Shakely D, Petzold M, et al. SYBR green real-time PCR-RFLP assay targeting the Plasmodium cytochrome b gene—a highly sensitive molecular tool for malaria parasite detection and species determination. PLoS ONE. 2015;10:e0120210.PubMedPubMedCentralCrossRef
77.
go back to reference Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood. 1997;90:2037–40.PubMedCrossRef Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood. 1997;90:2037–40.PubMedCrossRef
78.
go back to reference Chotivanich K, Udomsangpetch R, Mcgready R, Proux S, Newton P, Pukrittayakamee S, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis. 2002;10400:1538–41.CrossRef Chotivanich K, Udomsangpetch R, Mcgready R, Proux S, Newton P, Pukrittayakamee S, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis. 2002;10400:1538–41.CrossRef
79.
go back to reference Chotivanich K, Udomsangpetch R, Dondorp A, Williams T, Angus B, Simpson JA, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis. 2000;182:629–33.PubMedCrossRef Chotivanich K, Udomsangpetch R, Dondorp A, Williams T, Angus B, Simpson JA, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis. 2000;182:629–33.PubMedCrossRef
80.
go back to reference Ouédraogo AL, Guelbéogo WM, Cohuet A, Morlais I, King JG, Gonçalves BP, et al. A protocol for membrane feeding assays to determine the infectiousness of P. falciparum naturally infected individuals to Anopheles gambiae. Malaria World J. 2013;4:16. Ouédraogo AL, Guelbéogo WM, Cohuet A, Morlais I, King JG, Gonçalves BP, et al. A protocol for membrane feeding assays to determine the infectiousness of P. falciparum naturally infected individuals to Anopheles gambiae. Malaria World J. 2013;4:16.
81.
82.
go back to reference Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J. 2008;7:125.PubMedPubMedCentralCrossRef Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J. 2008;7:125.PubMedPubMedCentralCrossRef
83.
go back to reference Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis. 2013;207:1637–45.PubMedCrossRef Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis. 2013;207:1637–45.PubMedCrossRef
84.
go back to reference Okell LC, Drakeley CJ, Bousema T, Whitty CJM, Ghani AC. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med. 2008;5:e226.PubMedPubMedCentralCrossRef Okell LC, Drakeley CJ, Bousema T, Whitty CJM, Ghani AC. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med. 2008;5:e226.PubMedPubMedCentralCrossRef
85.
go back to reference Delves MJ, Ruecker A, Straschil U, Lelièvre J, Marques S, López-Barragán MJ, et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob Agents Chemother. 2013;57:3268–74.PubMedPubMedCentralCrossRef Delves MJ, Ruecker A, Straschil U, Lelièvre J, Marques S, López-Barragán MJ, et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob Agents Chemother. 2013;57:3268–74.PubMedPubMedCentralCrossRef
86.
go back to reference Betson M, Sousa-Figueiredo JC, Atuhaire A, Arinaitwe M, Adriko M, Mwesigwa G, et al. Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment. Parasitology. 2014;141:1880–90.PubMedCrossRef Betson M, Sousa-Figueiredo JC, Atuhaire A, Arinaitwe M, Adriko M, Mwesigwa G, et al. Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment. Parasitology. 2014;141:1880–90.PubMedCrossRef
87.
go back to reference Otienoburu SD, Suay I, Garcia S, Thomas NV, Srisutham S, Björkman A, et al. An online mapping database of molecular markers of drug resistance in Plasmodium falciparum: the ACT partner drug molecular surveyor. Malar J. 2019;18:12.PubMedPubMedCentralCrossRef Otienoburu SD, Suay I, Garcia S, Thomas NV, Srisutham S, Björkman A, et al. An online mapping database of molecular markers of drug resistance in Plasmodium falciparum: the ACT partner drug molecular surveyor. Malar J. 2019;18:12.PubMedPubMedCentralCrossRef
88.
go back to reference Ouji M, Augereau J, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination. Parasite. 2018;25:24.PubMedPubMedCentralCrossRef Ouji M, Augereau J, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination. Parasite. 2018;25:24.PubMedPubMedCentralCrossRef
89.
go back to reference Lee P, Ji D, Liu C, Rampao HS, Rosario VE, Lin I. Application of loop-mediated isothermal amplification for malaria diagnosis during a follow-up study in São Tomé. Malar J. 2012;11:408.PubMedPubMedCentralCrossRef Lee P, Ji D, Liu C, Rampao HS, Rosario VE, Lin I. Application of loop-mediated isothermal amplification for malaria diagnosis during a follow-up study in São Tomé. Malar J. 2012;11:408.PubMedPubMedCentralCrossRef
90.
go back to reference WHO. Defining and validating a measure of parasite resistance to sulfadoxine-pyrimethamine (SP) that would be indicative of the protective efficacy of SP for intermittent preventive treatment in infancy (SP-IPTi). Geneva: World Health Organization; 2009. WHO. Defining and validating a measure of parasite resistance to sulfadoxine-pyrimethamine (SP) that would be indicative of the protective efficacy of SP for intermittent preventive treatment in infancy (SP-IPTi). Geneva: World Health Organization; 2009.
91.
go back to reference Okell LC, Griffin JT, Roper C. Mapping sulphadoxine-pyrimethamnine resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa. Sci Rep. 2017;7:7389.PubMedPubMedCentralCrossRef Okell LC, Griffin JT, Roper C. Mapping sulphadoxine-pyrimethamnine resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa. Sci Rep. 2017;7:7389.PubMedPubMedCentralCrossRef
Metadata
Title
Evaluation of residual submicroscopic Plasmodium falciparum parasites 3 days after initiation of treatment with artemisinin-based combination therapy
Authors
Richard Mwaiswelo
Bill Ngasala
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2020
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-020-03235-3

Other articles of this Issue 1/2020

Malaria Journal 1/2020 Go to the issue